UK markets close in 1 hour 18 minutes

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
17.31-0.46 (-2.59%)
As of 09:30AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 71.40B
Enterprise value 89.96B
Trailing P/E 12.75
Forward P/E 9.30
PEG ratio (5-yr expected) 1.07
Price/sales (ttm)1.48
Price/book (mrq)6.24
Enterprise value/revenue 2.34
Enterprise value/EBITDA 9.18

Trading information

Stock price history

Beta (5Y monthly) 0.29
52-week change 3-18.82%
S&P500 52-week change 3-9.85%
52-week high 323.40
52-week low 313.48
50-day moving average 317.32
200-day moving average 318.38

Share statistics

Avg vol (3-month) 33.52k
Avg vol (10-day) 33.08k
Shares outstanding 54.09B
Implied shares outstanding 6N/A
Float 83.9B
% held by insiders 10.69%
% held by institutions 141.17%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.94
Forward annual dividend yield 45.29%
Trailing annual dividend rate 30.76
Trailing annual dividend yield 34.29%
5-year average dividend yield 45.37
Payout ratio 478.88%
Dividend date 312 Apr 2017
Ex-dividend date 416 Nov 2022
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin 35.65%
Operating margin (ttm)24.19%

Management effectiveness

Return on assets (ttm)8.36%
Return on equity (ttm)34.77%

Income statement

Revenue (ttm)38.44B
Revenue per share (ttm)9.56
Quarterly revenue growth (yoy)18.10%
Gross profit (ttm)22.66B
EBITDA 11.72B
Net income avi to common (ttm)4.46B
Diluted EPS (ttm)1.36
Quarterly earnings growth (yoy)783.10%

Balance sheet

Total cash (mrq)7.16B
Total cash per share (mrq)1.77
Total debt (mrq)22.12B
Total debt/equity (mrq)253.74
Current ratio (mrq)0.97
Book value per share (mrq)2.27

Cash flow statement

Operating cash flow (ttm)9.27B
Levered free cash flow (ttm)9.04B